BRAF and neoplasm: In the first dataset (GSE50509, Rizos et al.), 21 patients with BRAF-mutant metastatic melanoma were treated with BRAF inhibitors (BRAFi, dabrafenib or vemurafenib) and evaluated for best objective response (RECIST response, %) and progression-free survival (PFS) [16], followed by gene expression profiling of tumor samples taken pre-treatment and post-relapse.